Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

949 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, de Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Kjeldsen SE, et al. Among authors: oparil s. Blood Press. 2009;18(6):348-61. doi: 10.3109/08037050903460590. Blood Press. 2009. PMID: 20001655 Free article. Clinical Trial.
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, Hille DA, Lyle PA, Okin PM, Dahlöf B, Oparil S. Os I, et al. Among authors: oparil s. Hypertension. 2008 Apr;51(4):1103-8. doi: 10.1161/HYPERTENSIONAHA.107.105296. Epub 2008 Feb 7. Hypertension. 2008. PMID: 18259029 Clinical Trial.
Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Biederman RW, et al. Among authors: oparil s. Hypertension. 2008 Aug;52(2):279-86. doi: 10.1161/HYPERTENSIONAHA.108.109819. Epub 2008 Jul 7. Hypertension. 2008. PMID: 18606908 Free PMC article.
Achieving better blood pressure control.
Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. Hedner T, et al. Among authors: oparil s. Blood Press Suppl. 2008 Jun;1:3-4. doi: 10.1080/08038020802184504. Blood Press Suppl. 2008. PMID: 18705529 No abstract available.
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H. Olsen MH, et al. Among authors: oparil s. Am Heart J. 2009 Jan;157(1):177-84. doi: 10.1016/j.ahj.2008.08.011. Epub 2008 Oct 17. Am Heart J. 2009. PMID: 19081416 Clinical Trial.
949 results